Ranbaxy eyes U.S. drug launches with sales exclusivity

MUMBAI (Reuters) – Ranbaxy Laboratories, India's No.1 drugmaker by sales, plans to file three to four generic drug applications every year that can earn it a six-month marketing exclusivity in the United States, the company's chief executive said on Thursday. The first company that seeks approval from the U.S. Food and Drug Administration for a generic version of a patented medicine gets exclusive rights to sell it for 180 days after patent expiry. "We have a very ambitious growth plan for our U.S. …